Balyasny Asset Management
LEGN icon

Balyasny Asset Management’s Legend Biotech LEGN Stock Holding History

Balyasny Asset Management’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-375,000
Closed -$16.2M – 3215
2025
Q2 		$16.2M Buy
+375,000
New +$12.2M 0.02% 749
2025
Q1 		– Sell
-119,400
Closed -$3.89M – 3063
2024
Q4 		$3.89M Buy
+119,400
New +$4.95M 0.01% 1394

Other funds holding LEGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FBIL
First Beijing Investment Ltd Hong Kong $2.32B AUM 8.06% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Balyasny Asset Management's LEGN Position: Q1 2026 in Review

Balyasny Asset Management sold out of Legend Biotech (LEGN) in Q1 2026, closing a stake of 343,785 shares — an estimated $7.47M sold.

Balyasny Asset Management first reported a position in LEGN in Q2 2022 and held it in 9 quarters. The position peaked at $35.8M in Q4 2024. 191 funds tracked by Wall St. Rank hold LEGN as of Q1 2026.

  • Balyasny Asset Management reported no remaining Legend Biotech position as of Q1 2026 after selling out during the quarter.
  • Balyasny Asset Management sold 343,785 Legend Biotech shares in Q1 2026, an estimated $7.47M.
  • Balyasny Asset Management first reported a position in Legend Biotech in Q2 2022 and held it in 9 quarters.
  • Balyasny Asset Management's Legend Biotech position peaked at $35.8M in Q4 2024.
  • 191 funds tracked by Wall St. Rank held Legend Biotech as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.